Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors
Oncogenic kinases contribute to immunosuppression and modulate the tumor microenvironment in solid tumors. Increasing evidence supports the fundamental role of oncogenic kinase signaling networks in coordinating immunosuppressive tumor microenvironments. This has led to numerous studies examining th...
Main Authors: | Ahn, Ryuhjin (Author), Ursini-Siegel, Josie (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
Multidisciplinary Digital Publishing Institute,
2021-09-20T14:16:18Z.
|
Subjects: | |
Online Access: | Get fulltext |
Similar Items
-
Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors
by: Ryuhjin Ahn, et al.
Published: (2021-03-01) -
Can Pharmacological Receptor Tyrosine Kinase Inhibitors Sensitize Poor Outcome Breast Tumors to Immune-Based Therapies?
by: Josie eUrsini-Siegel
Published: (2013-02-01) -
Combining gemcitabine with checkpoint kinase inhibitors to sensitize pancreatic tumors
by: Saini, Priyanka
Published: (2015) -
Research Progress of Histone Deacetylase Inhibitor Combined with
Immune Checkpoint Inhibitor in the Treatment of Tumor
by: Chen FANG, et al.
Published: (2021-03-01) -
Retreatment with immune checkpoint inhibitors in solid tumors: a systematic review
by: Kaili Yang, et al.
Published: (2020-11-01)